COMROD ACQUIRES TRIAD RF SYSTEMS
Reaching Further Into Unmanned Systems and Satellite Markets
TAU,
The acquisition of Triad further positions COMROD as a premier radio ancillary manufacturer that helps customers reach further with cutting-edge technology. In addition to strengthening COMROD's RF capability and capacity, the combined companies will be able to cooperate on next-generation Radio Range Extension solutions. Triad's constant push to extend the limits of data and distance, combined with their RF support and applications engineering, will enhance COMROD's development and technical capabilities in
"After 75 years of continued business, we're excited to add the complimentary product range and the technical capabilities of Triad to the COMROD group. This acquisition will allow us to continue our longevity and become a premier communications system provider," said
Triad will maintain its branding and will serve the market under the moniker TRIAD RF, A COMROD COMPANY.
About COMROD
COMROD Communication AS is a leading international manufacturer of antennas, control systems, masts, and power supplies for the defense and commercial markets.
About TriadRF Systems
Triad RF Systems is an innovative designer and manufacturer of RF/Microwave amplifiers and integrated radio systems for challenging environments. Founded 10 years ago by three industry veterans with a combined 65 years of engineering expertise, Triad builds on an outstanding track record of providing high-performing products that meet the stringent SWaP requirements of military and commercial wireless communications, Satcom, radar, and ISR / electronic warfare applications.
Learn more at: www.comrod.com/triadrf
CONTACT:
Cell: +1 (216) 403-4838
Email: [email protected]
Website: www.comrod.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/comrod-acquires-triad-rf-systems-302122803.html
SOURCE COMROD Communication AS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
- Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals
- 3D AI Studio Launches Flow: Node-Based 3D Workflows That Run in the Browser With No GPU or Setup
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share

